SCHEMBL20809152

SCHEMBL20809152

Cc1ncc(-c2ccccn2)s1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.61
NPC1 O15118 6/20 0.61
RAB9A P51151 5/20 0.61
MAPT P10636 3/20 0.61
GLA P06280 2/20 0.61
LMNA P02545 3/20 0.48
POLB P06746 2/20 0.48
CCR1 P32246 2/20 0.48
CCR5 P51681 2/20 0.48
CCR8 P51685 2/20 0.48
CYP1A2 P05177 1/20 0.48
METAP1 P53582 1/20 0.48
BLM P54132 1/20 0.48
HIF1A Q16665 1/20 0.48
DOHH Q9BU89 1/20 0.48
P4HTM Q9NXG6 1/20 0.48
ATM Q13315 1/20 0.47
GAA P10253 1/20 0.45
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15671496 0.79 MAPK14 (0.42) KDM4ENPC1RAB9AMAPTGLA
SCHEMBL24958732 0.78 KDM4E (0.57) KDM4ENPC1RAB9AMAPTGLA
SCHEMBL146522 0.78 KDR (0.52)
SCHEMBL146382 0.78 KDM4E (0.75) KDM4ENPC1RAB9AMAPTGLA
SCHEMBL17889606 0.77 MAPK14 (0.61) KDM4ENPC1RAB9AMAPTGLA
SCHEMBL3069800 0.77 KDM4E (1.00) KDM4ENPC1RAB9AMAPTGLA
SCHEMBL8239921 0.77 KDM4E (0.55) KDM4ENPC1RAB9AMAPTGLA
SCHEMBL3827117 0.76 KDM4E (0.72) KDM4ENPC1RAB9AMAPTGLA
SCHEMBL15859041 0.76 CCR1 (0.54) KDM4EMAPTCCR1CCR8MAPK14
SCHEMBL11996720 0.75 ADORA2A (0.40) KDM4ENPC1RAB9AMAPTGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
CN-1056369-C Pyridazinone derivatives or their salts, processes of their production, and anti-shock agents containing them ISHIHARA SANGYO KAISHA (JP) 2000-09-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 KDM4E 725/4885NPC1 4881/4885RAB9A 270/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 KDM4E 723/4885NPC1 4882/4885RAB9A 345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.